Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA.
Cancer Lett. 2014 Jan 28;342(2):170-7. doi: 10.1016/j.canlet.2012.01.020. Epub 2012 Jan 27.
Epigenetic aberrations have been associated with cutaneous melanoma tumorigenesis and progression including dysregulated DNA gene promoter region methylation, histone modification, and microRNA. Several of these major epigenetic aberrations have been developed into biomarkers. Epigenetic biomarkers can be detected in tissue and in blood as circulating DNA in melanoma patients. There is strong evidence that biomarkers in cutaneous melanoma will have an important role as companions to therapeutics and overall patient management. Important progress has been made in epigenetic melanoma biomarker development and verification of clinical utility, and this review discusses some of the key current developments and existing challenges.
表观遗传异常与皮肤黑色素瘤的发生和发展有关，包括 DNA 基因启动子区域的异常甲基化、组蛋白修饰和 microRNA。其中一些主要的表观遗传异常已被开发成为生物标志物。在黑色素瘤患者的组织和血液中，如循环 DNA 中，可以检测到这些表观遗传生物标志物。有强有力的证据表明，皮肤黑色素瘤的生物标志物将作为治疗和整体患者管理的辅助手段发挥重要作用。在表观遗传黑色素瘤生物标志物的开发和临床实用性验证方面已经取得了重要进展，本综述讨论了一些当前的关键进展和存在的挑战。
